Investing

ImmunityBio : IBRX

IBRX

Stock Data

$7.65

$0.23 (2.92%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

ImmunityBio Inc is a trailblazer in the biotechnology sector, focusing on innovative therapies and vaccines to empower the immune system against cancers and infectious diseases. With a rich pipeline that includes immunotherapy, cell therapy, and cutting-edge vaccine technologies, the company is actively advancing treatments for a variety of cancers and pathogens, including COVID-19 and HIV. Based in San Diego, California, ImmunityBio's collaborative efforts extend to notable institutions and companies, aiming to revolutionize healthcare with its groundbreaking research.

All ImmunityBio Articles

1 Article

David Moadel | Jul 10, 2026 at 12:04 PM EDT

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors…